Rivaroxaban Impurity 138 | CAS 39229-33-9 - Request Quote
Rivaroxaban Impurity 138
| SZ CAT No: | SZ-R017212 |
| CAS No | 39229-33-9 |
| Mol.F. | C4H6Cl2O2 |
| Mol.Wt. | 157.0 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rivaroxaban Impurity 138 is chemically 2-(2-Chloroethoxy)acetyl chloride. Rivaroxaban Impurity 138 is supplied with detailed characterization data compliant with regulatory guideline. Rivaroxaban Impurity 138 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rivaroxaban.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 39229-33-9
Purchase 39229-33-9
Order 39229-33-9
Enquire 39229-33-9
price of 39229-33-9
39229-33-9 Supplier
39229-33-9 Manufacturer
39229-33-9 Exporter
buy high quality Rivaroxaban Impurity 138
Purchase Rivaroxaban Impurity 138
Rivaroxaban Impurity 138 suppliers
Rivaroxaban Impurity 138 manufacturers
Rivaroxaban Impurity 138 price
Order Rivaroxaban Impurity 138
Enquire Rivaroxaban Impurity 138
Rivaroxaban Impurity 138 cost
Rivaroxaban Impurity 138 Supplier
Rivaroxaban Impurity 138 Distributor
Rivaroxaban Impurity 138 for Method Validation
Rivaroxaban Reference Standard
Rivaroxaban Impurity 138 for ANDA Filing
Rivaroxaban Impurity 138 for Forced Degradation Studies
Rivaroxaban Impurity 138 Identification Standards
Rivaroxaban Impurity 138 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


